Ovarian Cancer
GCT1184-04: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
- Details
ClinicalTrials.gov ID:
NCT07225270
Diagnosis Type:
NA
USOR Number:
- Address
,
P: